AR125379A1 - Un fab anti-tslp con estabilidad mejorada - Google Patents

Un fab anti-tslp con estabilidad mejorada

Info

Publication number
AR125379A1
AR125379A1 ARP220101003A ARP220101003A AR125379A1 AR 125379 A1 AR125379 A1 AR 125379A1 AR P220101003 A ARP220101003 A AR P220101003A AR P220101003 A ARP220101003 A AR P220101003A AR 125379 A1 AR125379 A1 AR 125379A1
Authority
AR
Argentina
Prior art keywords
fab
tslp
vector
improved stability
nucleic acid
Prior art date
Application number
ARP220101003A
Other languages
English (en)
Spanish (es)
Inventor
Roland Wilhelm Kolbeck
Emma Suzanne Cohen
Catherine Eugenie Huntington
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of AR125379A1 publication Critical patent/AR125379A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP220101003A 2021-04-19 2022-04-19 Un fab anti-tslp con estabilidad mejorada AR125379A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21169183 2021-04-19

Publications (1)

Publication Number Publication Date
AR125379A1 true AR125379A1 (es) 2023-07-12

Family

ID=75588042

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101003A AR125379A1 (es) 2021-04-19 2022-04-19 Un fab anti-tslp con estabilidad mejorada

Country Status (19)

Country Link
US (1) US20240199730A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326767A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024516962A (cg-RX-API-DMAC7.html)
KR (1) KR20230172508A (cg-RX-API-DMAC7.html)
CN (1) CN117222665A (cg-RX-API-DMAC7.html)
AR (1) AR125379A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022263281A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021587A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216894A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003082A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015286A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230533A (cg-RX-API-DMAC7.html)
EC (1) ECSP23086870A (cg-RX-API-DMAC7.html)
IL (1) IL307651A (cg-RX-API-DMAC7.html)
MX (1) MX2023012266A (cg-RX-API-DMAC7.html)
PH (1) PH12023552762A1 (cg-RX-API-DMAC7.html)
SA (1) SA523451188B1 (cg-RX-API-DMAC7.html)
TW (1) TW202306982A (cg-RX-API-DMAC7.html)
WO (1) WO2022223514A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA129038C2 (uk) * 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
AR135161A1 (es) 2024-01-29 2026-07-08 Astrazeneca Ab Composiciones de fragmentos de unión a la linfopoyetina estromal tímica (tslp) y métodos de uso de las mismas
USD1126392S1 (en) 2024-05-16 2026-05-12 Astrazeneca Ab Inhaler
US20260034317A1 (en) 2024-05-20 2026-02-05 Medimmune Limited Inhaler and capsule for delivering thymic stromal lymphopoietin (tslp)-binding antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1306272C (zh) 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
EP3609917A1 (en) * 2017-04-12 2020-02-19 Amgen Inc. Treatment of asthma with anti-tslp antibody
JP7331298B2 (ja) * 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合tslp及びその使用
UA129038C2 (uk) * 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)

Also Published As

Publication number Publication date
MX2023012266A (es) 2023-10-24
EP4326767A1 (en) 2024-02-28
IL307651A (en) 2023-12-01
KR20230172508A (ko) 2023-12-22
CL2023003082A1 (es) 2024-04-19
BR112023021587A2 (pt) 2023-12-19
US20240199730A1 (en) 2024-06-20
CO2023015286A2 (es) 2024-02-05
CN117222665A (zh) 2023-12-12
SA523451188B1 (ar) 2025-06-22
WO2022223514A1 (en) 2022-10-27
AU2022263281A1 (en) 2023-11-09
TW202306982A (zh) 2023-02-16
PH12023552762A1 (en) 2024-04-15
CA3216894A1 (en) 2022-10-27
AU2022263281A9 (en) 2023-11-16
CR20230533A (es) 2024-04-05
ECSP23086870A (es) 2023-12-29
JP2024516962A (ja) 2024-04-18

Similar Documents

Publication Publication Date Title
AR039003A1 (es) Composiciones y metodos para alterar el contenido de tocotrienoles
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
AR086272A2 (es) Anticuerpos anti-factor d humanizados y sus usos
BR112017008108A2 (pt) incorporação de aminoácidos não naturais em proteínas
BR0107703A (pt) Flavivìrus recombinantes e processos para uso dos mesmos
ECSP23086870A (es) Un fab anti-tslp con estabilidad mejorada
AR110093A1 (es) D-psicosa 3-epimerasa y método para preparar d-psicosa utilizando la misma
MX2018005063A (es) Polipéptidos condicionalmente activos.
AR040446A1 (es) Defensinas de plantas
AR070693A1 (es) Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para obtenerlas a partir de la expresion del polipeptido de nitrato 2 (nrt2)
AR114960A1 (es) Proteína tolerante a herbicida, gen codificante y uso de la misma
AR081740A1 (es) Plantas que tienen modificados rasgos relacionados con el rendimiento y un metodo para producirlas
BR112014022467A2 (pt) transformantes de rasamsonia
AR102410A1 (es) Polipéptidos que tienen actividad xilanasa con una tasa de conversión alta de polisacáridos que contienen xilosa
AR122047A2 (es) Polipéptido recombinante aislado con actividad pesticida, composición pesticida, molécula de ácido nucleico, célula huésped, construcción de adn, vector, método para producir dicho polipéptido y método para producir una planta transgénica
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
MX2016010623A (es) Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo.
AR084107A1 (es) Plantas con mejoras en la utilizacion de nitrogeno y tolerancia al estres
AR087719A2 (es) Celula de planta transformada, cultivo de tejidos y planta transgenica
AR125461A1 (es) Células presentadoras de antígeno recombinante
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
MX2025003457A (es) Elementos para el desdireccionamiento de la expresión génica en el ganglio de la raíz dorsal y/o el hígado
AR127562A1 (es) ANTICUERPOS CONTRA EL FACTOR DE NECROSIS TUMORAL a HUMANO
AR050085A1 (es) Procedimiento para la generacion de plantas transgenicas con resistencia aumentada a patogenos por modificacion del contenido y/o la actividad de factores despolimerizantes de actina.
AR127169A1 (es) Composiciones y métodos para la prevención y/o tratamiento de la covid-19